

AMENDMENTS TO THE CLAIMS

1-34. (canceled)

35. (currently amended) A pharmaceutical composition comprising:

a therapeutically effective amount of cilostazol ;

a solubilizer selected from the group consisting of polyoxyl 40 castor oil, polyoxyl 35 castor oil, PEG-8 caprylic/capric glycerides, sorbitan monooleate, sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, PEG-20 sorbitan monooleate, glyceryl mono/dioleate, glyceryl caprylate/caprate, caprylic acid mono/diglycerides, and mono- and diacetylated monoglycerides, linoleoyl monoglycerides, lauroyl macrogol-32 glycerides, α -tocopherol, α -tocopherol acetate, α -tocopherol succinate, α -tocopherol polyethyleneglycol (200-8000 MW) succinate, α -tocopherol polyethylene glycol 400 succinate, dl- α -tocopherol polyethyleneglycol 1000 succinate, and d- α -tocopherol polyethyleneglycol 1000 succinate;

; and

a release modulator which synchronizes the release of the cilostazol and the solubilizer;

~~wherein the release of cilostazol and solubilizer are synchronized~~ wherein the cilostazol is from 0.5% to 50% w/w of the composition, the solubilizer is present from 15% w/w to 95% w/w of the composition, and the release modulator is from 1% to 50% w/w of the composition.

36-41. (canceled)

42. (currently amended) The pharmaceutical composition of claim 35, wherein the release modulator is an osmotic pump, ~~a dissolving salt or complex~~, an erodible matrix, an ion exchange resin, a wax, an insoluble carrier, a polymeric matrix, a polymeric coating, a fatty alcohol, a fatty acid, a tocol derivative, racemers, enantiomers, or mixtures thereof.

43. (previously presented) The pharmaceutical composition of claim 42, wherein the release modulator is a polymeric matrix, a polymeric coating, a wax, a fatty alcohol, a fatty acid, a tocol, racemers, enantiomers, or mixtures thereof.

44. (previously presented) The pharmaceutical composition of claim 43, wherein the polymeric matrix or polymeric coating is a cellulose, an acrylic polymer, a polyvinylpyrrolidone copolymer, a shellac, polyvinyl acetyl phthalate, a polysaccharide gum or mixtures thereof.

45. (previously presented) The pharmaceutical composition of claim 43, wherein the tocol is a tocol derivative selected from the group consisting of α -tocopherol, α -tocopherol acetate, α -tocopherol nicotinate, α -tocopherol succinate, α -tocopherol polyethyleneglycol succinate, α -tocopherol polyethylene glycol 400 succinate, racemers, enantiomers, or mixtures thereof.

46. (previously presented) The pharmaceutical composition of claim 43, wherein the release modulator is microcrystalline wax, hydrogenated vegetable oil, glycerol dibehenate, glycerol distearate, glycerol dipalmitate, glycerol palmitostearate, a cellulose, a lauroyl macrogol-32 glyceride, a stearyl macrogol-32 glyceride, calcium steroyl lactylate, stearic acid, stearyl alcohol, sucrose distearate, sucrose palmitate, sucrose dipalmitate, sorbitan monooleate, yellow

wax, white wax, nonionic emulsifying wax, carnauba wax, microcrystalline wax, cetyl ester wax or mixtures thereof.

47. (original) The pharmaceutical composition of claim 35, wherein the release is controlled over an extended period of time.

48. (currently amended) The pharmaceutical composition of claim 47, wherein the period of time is more than ~~about~~ 1 hour.

49. (currently amended) The pharmaceutical composition of claim 48, wherein the period of time is more than ~~about~~ 2 hours.

50. (currently amended) The pharmaceutical composition of claim 49, wherein the period of time is from ~~about~~ 2 hours to ~~about~~ 24 hours.

51. (currently amended) The pharmaceutical composition of claim 35, wherein the release of cilostazol and solubilizer are synchronized with a correlation coefficient of greater than ~~about~~ 0.80.

52. (original) The pharmaceutical composition of claim 35 including one or more additives.

53. (canceled)

54. (original) The pharmaceutical composition of claim 35, wherein the solubilizer is d- α -tocopherol polyethylene glycol 1000 succinate and the release modulator is α -tocopherol succinate.

55. (original) The pharmaceutical composition of claim 54 including one or more additives.

56. (original) The pharmaceutical composition of claim 55, wherein the solubilizer is d- α -tocopherol polyethylene glycol 1000 succinate, the release modulator is α -tocopherol succinate and the additive is polyethylene glycol.

57. (original) The pharmaceutical composition of claim 35, wherein the solubilizer is polyoxyl 40 hydrogenated castor oil and the release modulator is hydroxypropylmethylcellulose.

58. (original) The pharmaceutical composition of claim 35, wherein the solubilizer is polyoxyl 40 hydrogenated castor oil and the release modulator is glycerol dibehenate, glycerol palmitostearate, glycerol distearate, or mixtures thereof.

59. (currently amended) An oral dosage form comprising:

a therapeutically effective amount of cilostazol;

a solubilizer selected from the group consisting of polyoxyl 40 castor oil, polyoxyl 35 castor oil, PEG-8 caprylic/capric glycerides, sorbitan monooleate, sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, PEG-20 sorbitan monooleate, glyceryl mono/dioleate, glyceryl caprylate/caprate, caprylic acid mono/diglycerides, and mono- and diacetylated monoglycerides, linoleoyl monoglycerides, lauroyl macrogol-32 glycerides, α -tocopherol, α -tocopherol acetate, α -tocopherol succinate, α -tocopherol polyethyleneglycol (200-

8000 MW) succinate, α -tocopherol polyethylene glycol 400 succinate, d1- α -tocopherol polyethyleneglycol 1000 succinate, and d- α -tocopherol polyethyleneglycol 1000 succinate; and a release modulator which synchronizes the release of the cilostazol and the solubilizer; wherein the release of cilostazol and solubilizer are synchronized wherein the cilostazol is from 0.5% to 50% w/w of the composition, the solubilizer is present from 15% w/w to 95% w/w of the composition, and the release modulator is from 1% to 50% w/w of the composition.

60. (currently amended) A solid oral dosage form comprising:

a therapeutically effective amount of cilostazol;

a solubilizer which synchronizes the release of the cilostazol and itself, said solubilizer being selected from the group consisting of polyoxyl 40 castor oil, polyoxyl 35 castor oil, PEG-8 caprylic/capric glycerides, sorbitan monooleate, sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, PEG-20 sorbitan monooleate, glyceryl mono/dioleate, glyceryl caprylate/caprates, caprylic acid mono/diglycerides, and mono- and diacetylated monoglycerides, linoleoyl monoglycerides, lauroyl macrogol-32 glycerides, α -tocopherol, α -tocopherol acetate, α -tocopherol succinate, α -tocopherol polyethyleneglycol (200-8000 MW) succinate, α -tocopherol polyethylene glycol 400 succinate, d1- α -tocopherol polyethyleneglycol 1000 succinate, and d- α -tocopherol polyethyleneglycol 1000 succinate; and a release modulator; ~~wherein the release of cilostazol and solubilizer are synchronized~~ wherein the cilostazol is from 0.5% to 50% w/w of the composition, the solubilizer is present from 15% w/w to 95% w/w of the composition, and the release modulator is from 1% to 50% w/w of the composition..

61. (original) The dosage form of claim 60, wherein the dosage form is a capsule.

62-64. (canceled)

65. The pharmaceutical composition of claim 35, wherein the release modulator is the same compound as the solubilizer.

66. (new) The dosage form of claim 60, wherein the release modulator is an osmotic pump, a ~~dissolving salt or complex~~, an erodible matrix, an ion exchange resin, a wax, an insoluble carrier, a polymeric matrix, a polymeric coating, a fatty alcohol, a fatty acid, a tocol derivative, racemers, enantiomers, or mixtures thereof.

67. (new) The dosage form of claim 66, wherein the release modulator is a polymeric matrix, a polymeric coating, a wax, a fatty alcohol, a fatty acid, a tocol, racemers, enantiomers, or mixtures thereof.

68. (new) The dosage form of claim 67, wherein the polymeric matrix or polymeric coating is a cellulose, an acrylic polymer, a polyvinylpyrrolidone copolymer, a shellac, polyvinyl acetyl phthalate, a polysaccharide gum or mixtures thereof.

69. (new) The dosage form of claim 67, wherein the tocol is a tocol derivative selected from the group consisting of α -tocopherol, α -tocopherol acetate, α -tocopherol nicotinate, α -tocopherol succinate, α -tocopherol polyethyleneglycol succinate, α -tocopherol polyethylene glycol 400 succinate, racemers, enantiomers, or mixtures thereof.

70. (new) The dosage form of claim 67, wherein the release modulator is microcrystalline wax, hydrogenated vegetable oil, glycerol dibehenate, glycerol distearate, glycerol dipalmitate,

glycerol palmitostearate, a cellulose, a lauroyl macrogol-32 glyceride, a stearyl macrogol-32 glyceride, calcium steroyl lactylate, stearic acid, stearyl alcohol, sucrose distearate, sucrose palmitate, sucrose dipalmitate, sorbitan monooleate, yellow wax, white wax, nonionic emulsifying wax, carnauba wax, microcrystalline wax, cetyl ester wax or mixtures thereof.

71. (new) The dosage form of claim 60, wherein the release is controlled over an extended period of time.

72. (new) The dosage form of claim 47, wherein the period of time is more than 1 hour.

73. (new) The dosage form of claim 72, wherein the period of time is more than ~~about~~ 2 hours.

74. (new) The dosage form of claim 73, wherein the period of time is from ~~about~~ 2 hours to 24 hours.

75. (new) The dosage form of claim 60, wherein the release of cilostazol and solubilizer are synchronized with a correlation coefficient of greater than ~~about~~ 0.80.

76. (new) The dosage form of claim 60, including one or more additives.

77. (new) The dosage form of claim 60, wherein the solubilizer is d- α -tocopherol polyethylene glycol 1000 succinate and the release modulator is α -tocopherol succinate.

78. (new) The dosage form of claim 77 including one or more additives.

79. (new) The dosage form of claim 78, wherein the solubilizer is d- α -tocopherol polyethylene glycol 1000 succinate, the release modulator is α -tocopherol succinate and the additive is polyethylene glycol.

80. (new) The dosage form of claim 60, wherein the solubilizer is polyoxyl 40 hydrogenated castor oil and the release modulator is hydroxypropylmethylcellulose.

81. (new) The dosage form of claim 60, wherein the solubilizer is polyoxyl 40 hydrogenated castor oil and the release modulator is glycerol dibehenate, glycerol palmitostearate, glycerol distearate, or mixtures thereof.

82. (new) The dosage form of claim 60, wherein the release modulator is the same compound as the solubilizer.